Germany’s Merck Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...
Hosted on MSN13h
Merck KGaA Earnings Growth Beats Expectations
Merck KGaA reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...
Merck Foundation Marking "World Diabetes Day" by Providing out of 2080 Scholarships, 830 Scholarships for Diabetes and Hypertension in 52 Countries
BusinessWire India Accra [Ghana] Mumbai Maharashtra [India] November 14 Merck Foundation the philanthropic arm of Merck KGaA ...
Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...
bnnbloomberg13h
Merck KGaA Beats Estimates on Boost From Life Science Unit
(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...
FierceBiotech2d
Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono
Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...
Merck KGaA stock falls on weak Q3, soft outlook
Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...
pharmaphorum2d
Merck drug for rare tumour hits phase 3 target
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
pharmaphorum5d
Merck KGaA and Pfizer break into cancer immunotherapy
Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...